Filtered By:
Condition: Atrial Fibrillation
Management: Hospitals
This page shows you your search results in order of relevance. This is page number 20.
Order by Relevance | Date
Total 621 results found since Jan 2013.
Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: Status, obstacles, and strategies for improvement
Biosci Trends. 2022 Oct 30. doi: 10.5582/bst.2022.01278. Online ahead of print.ABSTRACTAtrial fibrillation (AF) and subsequent stroke and death have become major public health problems in China. Oral anticoagulant (OAC) forms the backbone of prevention of AF-related stroke. However, the quality of OAC use in AF patients in China is not clear. The focus of this narrative review is to summarize the current status of OAC therapy in China and compare it with the studies conducted internationally. In general, most data of OAC use in China were reported around 10-50%, with an increasing proportion of high-risk patients receiving...
Source: BioScience Trends - October 30, 2022 Category: Biomedical Science Authors: Luxiang Shang Yujiao Zhang Yang Zhao Baopeng Tang Yinglong Hou Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: Status, obstacles, and strategies for improvement
Biosci Trends. 2022 Oct 30. doi: 10.5582/bst.2022.01278. Online ahead of print.ABSTRACTAtrial fibrillation (AF) and subsequent stroke and death have become major public health problems in China. Oral anticoagulant (OAC) forms the backbone of prevention of AF-related stroke. However, the quality of OAC use in AF patients in China is not clear. The focus of this narrative review is to summarize the current status of OAC therapy in China and compare it with the studies conducted internationally. In general, most data of OAC use in China were reported around 10-50%, with an increasing proportion of high-risk patients receiving...
Source: BioScience Trends - October 30, 2022 Category: Biomedical Science Authors: Luxiang Shang Yujiao Zhang Yang Zhao Baopeng Tang Yinglong Hou Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: Status, obstacles, and strategies for improvement
Biosci Trends. 2022 Oct 30. doi: 10.5582/bst.2022.01278. Online ahead of print.ABSTRACTAtrial fibrillation (AF) and subsequent stroke and death have become major public health problems in China. Oral anticoagulant (OAC) forms the backbone of prevention of AF-related stroke. However, the quality of OAC use in AF patients in China is not clear. The focus of this narrative review is to summarize the current status of OAC therapy in China and compare it with the studies conducted internationally. In general, most data of OAC use in China were reported around 10-50%, with an increasing proportion of high-risk patients receiving...
Source: BioScience Trends - October 30, 2022 Category: Biomedical Science Authors: Luxiang Shang Yujiao Zhang Yang Zhao Baopeng Tang Yinglong Hou Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: Status, obstacles, and strategies for improvement
Biosci Trends. 2022 Oct 30. doi: 10.5582/bst.2022.01278. Online ahead of print.ABSTRACTAtrial fibrillation (AF) and subsequent stroke and death have become major public health problems in China. Oral anticoagulant (OAC) forms the backbone of prevention of AF-related stroke. However, the quality of OAC use in AF patients in China is not clear. The focus of this narrative review is to summarize the current status of OAC therapy in China and compare it with the studies conducted internationally. In general, most data of OAC use in China were reported around 10-50%, with an increasing proportion of high-risk patients receiving...
Source: BioScience Trends - October 30, 2022 Category: Biomedical Science Authors: Luxiang Shang Yujiao Zhang Yang Zhao Baopeng Tang Yinglong Hou Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: Status, obstacles, and strategies for improvement
Biosci Trends. 2022 Oct 30. doi: 10.5582/bst.2022.01278. Online ahead of print.ABSTRACTAtrial fibrillation (AF) and subsequent stroke and death have become major public health problems in China. Oral anticoagulant (OAC) forms the backbone of prevention of AF-related stroke. However, the quality of OAC use in AF patients in China is not clear. The focus of this narrative review is to summarize the current status of OAC therapy in China and compare it with the studies conducted internationally. In general, most data of OAC use in China were reported around 10-50%, with an increasing proportion of high-risk patients receiving...
Source: BioScience Trends - October 30, 2022 Category: Biomedical Science Authors: Luxiang Shang Yujiao Zhang Yang Zhao Baopeng Tang Yinglong Hou Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: Status, obstacles, and strategies for improvement
Biosci Trends. 2022 Oct 30. doi: 10.5582/bst.2022.01278. Online ahead of print.ABSTRACTAtrial fibrillation (AF) and subsequent stroke and death have become major public health problems in China. Oral anticoagulant (OAC) forms the backbone of prevention of AF-related stroke. However, the quality of OAC use in AF patients in China is not clear. The focus of this narrative review is to summarize the current status of OAC therapy in China and compare it with the studies conducted internationally. In general, most data of OAC use in China were reported around 10-50%, with an increasing proportion of high-risk patients receiving...
Source: BioScience Trends - October 30, 2022 Category: Biomedical Science Authors: Luxiang Shang Yujiao Zhang Yang Zhao Baopeng Tang Yinglong Hou Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: Status, obstacles, and strategies for improvement
Biosci Trends. 2022 Oct 30. doi: 10.5582/bst.2022.01278. Online ahead of print.ABSTRACTAtrial fibrillation (AF) and subsequent stroke and death have become major public health problems in China. Oral anticoagulant (OAC) forms the backbone of prevention of AF-related stroke. However, the quality of OAC use in AF patients in China is not clear. The focus of this narrative review is to summarize the current status of OAC therapy in China and compare it with the studies conducted internationally. In general, most data of OAC use in China were reported around 10-50%, with an increasing proportion of high-risk patients receiving...
Source: BioScience Trends - October 30, 2022 Category: Biomedical Science Authors: Luxiang Shang Yujiao Zhang Yang Zhao Baopeng Tang Yinglong Hou Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: Status, obstacles, and strategies for improvement
Biosci Trends. 2022 Nov 20;16(5):317-329. doi: 10.5582/bst.2022.01278. Epub 2022 Oct 30.ABSTRACTAtrial fibrillation (AF) and subsequent stroke and death have become major public health problems in China. Oral anticoagulant (OAC) forms the backbone of prevention of AF-related stroke. However, the quality of OAC use in AF patients in China is not clear. The focus of this narrative review is to summarize the current status of OAC therapy in China and compare it with the studies conducted internationally. In general, most data of OAC use in China were reported around 10-50%, with an increasing proportion of high-risk patients ...
Source: BioScience Trends - October 30, 2022 Category: Biomedical Science Authors: Luxiang Shang Yujiao Zhang Yang Zhao Baopeng Tang Yinglong Hou Source Type: research
